Furthermore, the use of other models of experimental hypertension may lead to different results, e.g., as mentioned above, chronic administration of the FAAH inhibitor URB597 did not affect BP in SHR, but reduced it in the deoxycorticosterone acetate (DOCA)-salt model of secondary hypertension [16]. The gene discussed is FAAH; the disease is secondary hypertension.